Blinatumomab, a bispecific T cell engager antibody, by binding to CD3 on the surface of T cells and CD19 on leukemia cells, initiates T cell receptor-mediated activation and killing of CD19-positive B-ALL [58]. Here, CD19 is linked to leukemia.